This could explain why conditions like cancer cachexia, where fat loss and anorexia contribute to a rapid decrease in muscle function, may improve with ghrelin administration while other more chronic conditions where food intake and fat mass are preserved such as sarcopenic obesity benefit more from long‐term ghrelin deletion. Here, GHRL is linked to obesity due to melanocortin 4 receptor deficiency.